34 results about "Glioma cell lines" patented technology

The invention discloses a semen lepidii anti-tumor effective component, a preparation method of the semen lepidii anti-tumor effective component and an application of the semen lepidii anti-tumor effective component in the field of anti-tumor. The preparation method comprises the following steps of: extracting semen lepidii (roasted) with water; and extracting with ethyl acetate and water saturated n-butyl alcohol sequentially; collecting water saturated n-butyl alcohol extract; separating with a silica (200 to 300 meshes) column; and performing gradient elution with dichloromethane-methanol in different proportions, wherein the dichloromethane-methanol (5:1) elution part is a semen lepidii anti-tumor effective part. The part has a remarkable effect of inhibiting U251 (glioma cell line), HepG2 (human hepatoma cell line), SGC (human gastric carcinoma cell), mcf-7 (human breast cancer cell) and SCLC (lung carcinoma cell), and can be used for preparing an anti-tumor medicament.

The invention relates to a glioma cell line. The glioma cell line is glioma cells infected by a virus vector. The virus vector comprises ITR (inverted terminal repeat), a promoter, a photosensitive gene, a green fluorescence labeling gene and ITR, which are sequentially connected. The glioma cell line is specifically marked by the light-sensing gene, and can generate stable light current under induction and stimulation of light, so that the glioma cell line can be selectively performed with specific regulation with light. The invention further provides a construction method of the glioma cell line.

The invention discloses an application of low-temperature plasma combined with metformin, in particular the application of low-temperature plasma combined with metformin to non-therapeutically induce glioma cell death in vitro. The application of the combination of low-temperature plasma and metformin in in vitro non-therapeutic induction of glioma cell death provided by the present invention shows that the combination of low-temperature plasma and metformin has obvious effects on glioma cell lines U251 and U87 cells cultured in vitro Synergistic inhibitory effect, can significantly induce cell death. The present invention is used for non-disease treatment, but for in vitro research. The scheme of the application of the combination of metformin and low-temperature plasma in inducing the death of glioma provided by the present invention can be used to study the combination of low-temperature plasma and metformin in glioma. It provides a new strategy for the application of glioma treatment, in order to provide new ideas for the design of new products or new programs for the treatment of glioma.

The invention provides miR-124-containing glioma cell exosomes, a preparation method and application thereof, and belongs to the technical field of central nervous system damage repairing drugs. A method for preparing glioma cell exosomes containing miR-124, the supernatant obtained by culturing a glioma cell line is subjected to solid-liquid separation; the separated exosomes and miR-124 are mixed and incubated together to obtain a Glioma cell exosomes of miR‑124. The exosomes prepared above can effectively bind to cholesterol-modified miR-124 and be absorbed by reactive astrocytes, significantly increase the expression of miR-124 in reactive astrocytes, and inhibit astrocytes. Activation and scarring. Therefore, the present invention also provides the application of miR-124-containing glioma cell exosomes in the preparation of a drug for inhibiting astrocyte activation and / or glial scar formation, thereby treating central nervous system injury diseases.

The invention discloses the application of a crRNA-mediated CRISPR / Cas13a gene editing system in tumor cells. In the U87 glioma cell line, the Cas13a protein of the present invention can be mediated by a single-stranded crRNA to a complementary target RNA and cut. At the same time, Cas13a protein can also trigger the effect of joint shearing in eukaryotic cells, that is, after starting to cut the first entry of RNA, Cas13a protein will randomly cut other RNAs encountered without purpose, thereby reducing Tumor cell index, inhibition of tumor formation rate and tumor size in mice and other effects of inhibiting and killing tumors. The invention provides a new method for inhibiting or killing tumor cells, and lays the foundation for the application of the random shearing effect of the CRISPR-Cas13 system in eukaryotic cells.

The invention relates to a method for researching a function of promoting brain glioma proliferation by an MDK gene and application of the MDK gene. The method comprises the following steps: (1) analyzing MDK expression of a glioma cell line through RT-qPCR, (2) carrying out lentivirus-mediated overexpression and MDK knockout, (3) interfering the influence of MDK gene expression on glioma cell proliferation, and (4) analyzing and detecting the conditions of P-PI3K, PI3K, P-Akt, Akt, p-ERK, N-cadherin, vimentin and beta-catenin in the glioma cell line which interferes with MDK gene expression through Western blot. The PI3K / AKT pathway is a glioma cell proliferation mechanism mediated by the MDK. The invention provides a new thought for treating glioma, and provides a new way for researching glioma drug treatment targets.

The present invention provides a TOP2A inhibition by temozolomide useful for predicting glioblastoma patient's survival. Glioblastoma (GBM) is the most common, malignant primary adult brain tumor. The conventional treatments for GBM, include surgery, radiation, and chemotherapy which have only modestly improved patient survival. The patients with GBM expressing higher TOP2A transcript levels had better prognosis. More interestingly, the present invention reports that temozolomide is an inhibitor of TOP2A activity in vitro. The present invention further shows that siRNA knock down of TOP2A rendered a glioma cell line resistant to temozolomide chemotherapy. Thus it is demonstrated for the first time that temozolomide is a TOP2A inhibitor and establishes that TOP2A transcript levels determines the chemosensitivity of glioblastoma to temozolomide therapy thus explaining the very high levels of TOP2A transcript being a good prognostic indicator in GBM patients receiving temozolomide chemotherapy.

The present invention relates the application of a human source dcf1 gene in the inhibition of U251 glioma cell line proliferation and in the induction of U251 glioma cell line apoptosis. The present invention makes judgments for dcf1-induced U251 cell line apoptosis by the methods of immune electron microscope, atomic force microscope, CCK8 proliferation detection, JC-1 staining, and nude mouce tumor heterotopic transplantation. The results show that: the dcf1 causes mitochondrial structure lesion and membrane potential reduction by locating in mitochondria, thereby causing apoptosis-related gene expression change, and eventually leading to apoptosis. The nude mouce experiments show that the dcf1 can significantly reduce glioma tumor volume and inhibit tumor growth.

The invention discloses a bridge molecule 1-siRNA interference sequence and a fusion expression vector thereof, and belongs to the technical field of biology. A fragment of synthesized bridge molecule1-siRNA interference sequence can reduce the expression of bridge molecule 1 protein, and generate inhibiting effect on cellular infiltration and diffusion function participated by the bridge molecule 1 protein; and after transfecting a human glioma cell line, the bridge molecule 1-siRNA fusion expression vector can specifically degrade bridge molecules 1mRNA complemented with the fusion expression vector, inhibit in vitro migration capability and chemotactic capability of malignant glioma LN-229 cells, inhibit in vitro adhesive capability and invasion capability of the malignant glioma LN-229 cells, reduce infiltration and diffusion capabilities of tumor cells, and provide a feasible technological measure for gene therapy of tumor.

The invention discloses application of psoromic acid in the preparation of medicine for treating brain glioma and acute myeloid leukemia. The psoromic acid plays an obvious role in inhibiting the growth of a human brain glioma cell line U87MG and a human erythroid leukemia cell line TF-1. The psoromic acid belongs to natural products and has the characteristics of low toxic or side effects and high bioavailability when the psoromic acid is used for treating brain glioma and acute myeloid leukemia, thereby having certain clinical use value.

The invention discloses a cytoskeletal binding protein siRNA (small interfering ribonucleic acid) interfering sequence, a fusion expression vector thereof and medical application of the same, belonging to the field of biological pharmacy. The invention designs a segment of cytoskeletal binding protein siRNA interfering sequence, and synthesizes the fusion expression vector of the cytoskeletal binding protein siRNA interfering sequence; after the fusion expression vector is transfected into a human glioma cell line, the fusion expression vector can specifically degrade the cytoskeletal binding protein messenger RNA (mRNA) complementary to the fusion expression vector to reduce the expression of the cytoskeletal binding protein in the human glioma cells; and the fusion expression vector can effectively inhibit the migration, adhesion and invasion abilities of the human glioma cells, has an effect on inhibiting the human glioma cellular infiltration and metastasis, and provides a feasible technical means for gene therapy for tumor patients.

The invention discloses combined application of low-temperature plasma and ascorbic acid, and particularly relates to combined application of a culture medium irradiated by the low-temperature plasmaand the ascorbic acid in in-vitro non-therapeutic induction of glioma cell death. It is shown that the culture medium irradiated by the low-temperature plasma and the ascorbic acid are combined to have an obvious synergistic inhibition effect on glioma cell lines U251 and U87 cultured in vitro, and cell death can be remarkably induced. Through the scheme provided by the invention, a new strategy can be provided for researching the combined application of low-temperature plasma and ascorbic acid in glioma treatment, and a new thought is expected to be provided for designing a new product or a new scheme for treating glioma.

The invention discloses a new application of isojacareubin. The new application is meant that isojacareubin as an active ingredient is used in preparation of an antitumor pharmaceutical preparation. Pharmacological tests prove that, isojacareubin has an obvious inhibition effect on growth of U87 human brain glioma cell lines, BXPC-3 human pancreatic cancer cell lines, NCI-2126 human lung cancer cell lines, PANC-1 human pancreatic cancer cell lines, A549 human non small cell lung cancer cell lines, AGs human gastric cancer cell lines, A375 human melanoma cell lines, MCF-7 human breast cancer cell lines, MDA-MB-231 human breast cancer cell lines and SMMC-7721 human liver cancer cell lines, has significant antitumor activity, can be expected to be used as the active ingredient for the preparation of the antitumor pharmaceutical preparation, and has medicinal prospects.